Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind ...

Overview: Real-time voice interaction is becoming a defining feature of next-generation AI applications. From conversational ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, Vertex's revenue soared 11% to more than $3 billion -- that's with net ...

One fund just doubled down on a beaten-down tax-tech leader—here’s what they may be seeing that the market isn’t.

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best large cap stocks to invest in for the long term. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was initiated with an Outperform ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label expansion and stronger commercial uptake.

These companies could innovate their way to success.

If the trends of the first three quarters continue in the fourth, the amount of money raised by Bay State startups could be ...

Vertex Pharmaceuticals Incorporated ( VRTX) Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM EST ...